ESiOR Oy’s Post

Finland, its people and its economy benefit directly from industry run clinical trials held in the country! A recent study by Lääketeollisuus ry / Pharma Industry Finland and ESiOR Oy published last week shows that clinical drug trials have significant societal benefits for Finland. The value of one clinical trial for patient care is estimated to be approximately EUR 1.2 million and the societal value to the Finnish healthcare system approximately EUR 10 million. At the same time a few of weeks ago PIF released a report indicating the investments that the pharmaceutical industry in Finland did in 2023. While overall they significantly increased year on year, it was mostly driven by increases in domestic production. Clinical trial investments were significantly lower and continued a downward trend that started 10 years ago. It is critical to break this trend if we truly want our people to have access to the best possible treatment options and our scientific community to be part of the develoment of these treatments. In order to halt the decline in clinical trials and attract healthcare investments to Finland, we must continue to develop our healthcare system together. This is the only way we can maintain our competitiveness and secure even faster access to new, innovative medical treatments for Finnish patients. Read more at the link here https://lnkd.in/dzz428Ah #clinicaltrials #innovation #kliininenlääketutkimus #innovaatiot #suominousuun #BMSSuomi #BMS_Employee